We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
Read MoreHide Full Article
In the latest close session, Astrazeneca (AZN - Free Report) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.59%.
Heading into today, shares of the pharmaceutical had gained 0.82% over the past month, lagging the Medical sector's gain of 1.12% and outpacing the S&P 500's loss of 0.21%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.09, signifying a 3.81% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $15.76 billion, indicating a 5.81% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $4.6 per share and a revenue of $58.91 billion, demonstrating changes of +11.92% and +8.95%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Currently, Astrazeneca is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is presently being traded at a Forward P/E ratio of 19.51. This expresses a premium compared to the average Forward P/E of 18.17 of its industry.
Investors should also note that AZN has a PEG ratio of 1.66 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.66.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 87, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
In the latest close session, Astrazeneca (AZN - Free Report) was up +1.93% at $91.56. The stock's change was more than the S&P 500's daily loss of 0.16%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 0.59%.
Heading into today, shares of the pharmaceutical had gained 0.82% over the past month, lagging the Medical sector's gain of 1.12% and outpacing the S&P 500's loss of 0.21%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. The company's upcoming EPS is projected at $1.09, signifying a 3.81% increase compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $15.76 billion, indicating a 5.81% growth compared to the corresponding quarter of the prior year.
For the full year, the Zacks Consensus Estimates project earnings of $4.6 per share and a revenue of $58.91 billion, demonstrating changes of +11.92% and +8.95%, respectively, from the preceding year.
Any recent changes to analyst estimates for Astrazeneca should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% higher. Currently, Astrazeneca is carrying a Zacks Rank of #3 (Hold).
In terms of valuation, Astrazeneca is presently being traded at a Forward P/E ratio of 19.51. This expresses a premium compared to the average Forward P/E of 18.17 of its industry.
Investors should also note that AZN has a PEG ratio of 1.66 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.66.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 87, finds itself in the top 36% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.